Siplizumab combination therapy with belatacept or abatacept broadly inhibits human T cell alloreactivity in vitro.

MLA

Cvetkovski, Filip, et al. “Siplizumab Combination Therapy with Belatacept or Abatacept Broadly Inhibits Human T Cell Alloreactivity in Vitro.” American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons, vol. 23, no. 10, Oct. 2023, pp. 1603–11. EBSCOhost, https://doi.org/10.1016/j.ajt.2023.05.032.

APA

Cvetkovski, F., Razavi, R., Sellberg, F., Berglund, E., & Berglund, D. (2023). Siplizumab combination therapy with belatacept or abatacept broadly inhibits human T cell alloreactivity in vitro. American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 23(10), 1603–1611. https://doi.org/10.1016/j.ajt.2023.05.032

Chicago

Cvetkovski, Filip, Ronia Razavi, Felix Sellberg, Erik Berglund, and David Berglund. 2023. “Siplizumab Combination Therapy with Belatacept or Abatacept Broadly Inhibits Human T Cell Alloreactivity in Vitro.” American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons 23 (10): 1603–11. doi:10.1016/j.ajt.2023.05.032.